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Abstract
Background: There is strong evidence showing that voluntary medical male circumcision (VMMC) reduces HIV incidence in
men. To inform the VMMC policies and goals of 13 priority countries in eastern and southern Africa, we estimate the impact
and cost of scaling up adult VMMC using updated, country-specific data.
Methods and Findings: We use the Decision Makers’ Program Planning Tool (DMPPT) to model the impact and cost of
scaling up adult VMMC in Botswana, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, Tanzania,
Uganda, Zambia, Zimbabwe, and Nyanza Province in Kenya. We use epidemiologic and demographic data from recent
household surveys for each country. The cost of VMMC ranges from US$65.85 to US$95.15 per VMMC performed, based on a
cost assessment of VMMC services aligned with the World Health Organization’s considerations of models for optimizing
volume and efficiencies. Results from the DMPPT models suggest that scaling up adult VMMC to reach 80% coverage in the
13 countries by 2015 would entail performing 20.34 million circumcisions between 2011 and 2015 and an additional 8.42
million between 2016 and 2025 (to maintain the 80% coverage). Such a scale-up would result in averting 3.36 million new
HIV infections through 2025. In addition, while the model shows that this scale-up would cost a total of US$2 billion
between 2011 and 2025, it would result in net savings (due to averted treatment and care costs) amounting to US$16.51
billion.
Conclusions: This study suggests that rapid scale-up of VMMC in eastern and southern Africa is warranted based on the
likely impact on the region’s HIV epidemics and net savings. Scaling up of safe VMMC in eastern and southern Africa will
lead to a substantial reduction in HIV infections in the countries and lower health system costs through averted HIV care
costs.
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Three randomized controlled trials have shown that voluntary
medical male circumcision (VMMC) reduces heterosexual HIV
acquisition in men by up to 60% [1–3]. On the basis of these trial
results, the World Health Organization (WHO) and the Joint
United Nations Programme on HIV/AIDS (UNAIDS) now
recommend that VMMC be offered to heterosexual men in
combination with other effective HIV risk reduction interventions
in settings with generalized HIV epidemics and where a
substantial proportion of men are not circumcised [4].
The long-term population-level impact of implementing and
scaling up VMMC services is expected to be considerable in terms
of HIV infections averted, as well as net savings associated with the
reduced need for treatment, care, and support of infected
individuals. Previous model-based studies estimated that VMMC
scale-up in countries with generalized HIV epidemics could result
in substantial reductions in HIV transmission and prevalence over
time among both men and women [3,5–9]. A recent review of
these studies concluded that one HIV infection could be averted
for every five to 15 VMMCs performed [10]. Modeling studies
also have found that expansion of VMMC services produces net
savings when compared to lifetime HIV treatment costs [8,9,11].
In addition, studies have shown VMMC to be protective against
some other sexually transmitted infections (STIs) in both men and
women. VMMC has been found to reduce the risk of herpes
simplex virus-2 in men [12] and human papillomavirus in men
[12–15] and their female partners [16], and is associated with a
reduction in the risk of genital ulcer disease [3,17] and genital
cancers [18–20] in both men and women.
In light of this evidence, in early 2007, WHO and UNAIDS
identified the following priority countries for VMMC scale-up:
Botswana, Lesotho, Malawi, Mozambique, Namibia, Rwanda,
South Africa, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe,
and Nyanza Province in Kenya (Figure 1). Four years later, most
of these 13 countries have developed plans for VMMC scale-up
and are at various stages of program implementation. However,
with a few exceptions (e.g., Nyanza Province in Kenya and the
Iringa Region in Tanzania), progress in expanding VMMC
services remains slow [21].
There is consensus that VMMC scale-up will require substantial
funding and massive efforts to adequately train personnel, equip
facilities, and ensure the regular distribution of necessary
commodities—mostly in settings with weak health systems and
resource constraints. As background for the scale-up of safe
VMMC, WHO, UNAIDS, and collaborating partners have
developed a number of guidelines and toolkits, including a
recommended minimum package of VMMC services [22] and
clinical guidelines for the provision of these services [23]. In
addition, to facilitate a more rapid scale-up of safe VMMC, WHO
has outlined considerations for models to optimize the volume and
efficiency (MOVE) of VMMC services [24]. Central to these
considerations is the efficient use of facility space through the
dedication of multiple surgical beds to one surgical team and the
coordination of client flow; the efficient use of staff time through
task shifting and task sharing, including deployment of non-
physicians to complete all or specific steps in VMMC surgery; and
the bundling of commodities and supplies required to perform
VMMC, including consumable materials and surgical instruments
[24].
To support decision making and planning for VMMC scale-up,
the United States Agency for International Development (USAID)
Health Policy Initiative collaborated with UNAIDS to develop the
Decision Makers’ Program Planning Tool (DMPPT) [25]. This
modeling tool, which has been reviewed by an expert panel [10],
allows analysts and decision makers to estimate the epidemiologic
impact and cost of alternative programmatic options for scaling up
VMMC.
The objective of this study is to estimate the country-specific
epidemiologic impact and the cost and net savings associated with
scaling up VMMC services based on MOVE considerations in the
13 priority countries in eastern and southern Africa. The
perspective that is taken is that of governments and their
international partners in their roles as health program funders.
To do this, we run country-specific DMPPT models and explore
how the results for each country vary by VMMC effectiveness,
VMMC coverage level, time to scale-up, level of post-circumcision
behavior change, VMMC unit cost, and antiretroviral therapy
(ART) cost.
This study expands on previous related work [8,9,11] in several
ways. All of our analyses are country-specific and based on the
most recent data on HIV and male circumcision prevalence
available. Our calculations provide more comprehensive estimates
of VMMC-related costs than was the case in previous studies since
they include costs for supply chain management and waste
management, as per WHO’s recent recommendations for efficient
VMMC scale-up [24]. In addition, we provide country-specific
results on impact (VMMC per HIV infection averted), cost-
effectiveness (cost per HIV infection averted) and cost savings (cost
of VMMC relative to the averted cost of lifetime provision of
ART).
Methods
The Model
The DMPPT is a Microsoft-Excel-based modeling tool that
estimates the epidemiologic impact (HIV infections averted) and
the cost and net savings associated with different programming
scenarios for VMMC scale-up. A list of all the equations used in
the model can be found in Table S1. Additional details, including
a copy of the workbook and the model manual [25], can be found
at http://www.malecircumcision.org/programs/DMPPT.html.
The DMPPT is a compartmental deterministic model in which
the population is disaggregated into four sex/age groups (females
ages 15–24 y, males ages 15–24 y, females ages 25–49 y, and
males ages 25–49 y). For each population group, a susceptible and
infected population is described [26,27]. The susceptible popula-
tion is increased by people aging into it (15-y-olds entering the
younger age group and 25-y-olds leaving the younger age group
and entering the older age group) and decreased by non-AIDS
deaths and new infections. The infected population is increased by
new infections and decreased by non-AIDS deaths, AIDS deaths,
and aging out.
In the model, HIV incidence (the proportion of the susceptible
population becoming infected each year) is the product of HIV
prevalence in the population and the force of infection. The force
of infection is determined by the base rate of infection (which is a
fitting parameter specific to each population group), changes in
behavior, and changes due to male circumcision. Changes in
behavior are assumed to occur as the epidemic progresses because
of two key influences. Individuals with the riskiest behaviors are
assumed to become infected first and die sooner than the rest of
the population. Also, as AIDS deaths accumulate, a powerful effect
on individual behavior is assumed, as those who know someone
who has died from AIDS are motivated to adopt safer behaviors.
Thus, the force of infection can drop over time as the cumulative
number of AIDS deaths increases. The amount of the effect is
determined by a fitting parameter that produces the best fit to the
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interventions is incorporated through exogenous reductions in the
force of infection. The effect of male circumcision on the force of
infection is simply the increase in the prevalence of male
circumcision multiplied by the reduction in susceptibility due to
circumcision.
For each scenario of interest, the DMPPT model generates two
projections: a baseline projection, in which male circumcision
coverage is held constant at the pre-scale-up level, and a scale-up
projection where VMMC coverage is scaled up to the desired
coverage level. In the baseline projection, new infections increase
over time in response to the initial force of infection. This causes
HIV prevalence to rise rapidly in early years. The force of
infection then declines somewhat as AIDS deaths accumulate and
prevalence stabilizes. Implementation of a male circumcision
program can cause a further reduction in the force of infection
(depending on the increase in male circumcision coverage), leading
to a decline in new infections and HIV prevalence. There is some
concern that men who undergo circumcision may develop a false
sense of protection against HIV and thereafter decrease or even
stop previously implemented protective behaviors [28,29]. Post-
circumcision behavior change is modeled in the DMPPT as a
proportional change in the force of infection, with a VMMC scale-
up scenario in which circumcision does not lead to any behavior
change being modeled as having a 0% post-circumcision behavior
change effect.
The DMPPT model calculates the yearly cost of the additional
circumcisions (the number of VMMCs required above and beyond
those occurring at pre-scale-up coverage levels) as the sum of the
additional circumcisions performed per annum times the VMMC
unit cost. The model also calculates the net savings associated with
HIV infections averted and the subsequent treatment costs
averted.
Demographic, Epidemiologic, and Sexual Behavior Data
The demographic and epidemiologic inputs required to
estimate the epidemiologic impact of VMMC scale-up include
the following:
N Demographic data—size of adult population by sex and age
group, adult population growth rate, crude birth rate, crude
death rate, proportion of population surviving to age 15 y, pre-
scale-up male circumcision prevalence.
N Epidemiologic data—HIV prevalence among adults by sex
and age group; effectiveness of male circumcision in
preventing HIV infection; underlying HIV transmission factors
based on scientific evidence, including probability of transmis-
sion from mother to child; fertility reduction due to HIV.
Figure 1. Geographic distribution of HIV and male circumcision prevalence. For the 13 countries included in the study, the map on the left
indicates the prevalence of HIV in adults ages 15 to 49 y. The map on the right indicates the percentage of men who are circumcised.
doi:10.1371/journal.pmed.1001132.g001
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group, post-circumcision behavior change (change in condom
use and/or change in number of sexual partners following
VMMC resulting from lowered perceived risk).
We obtained the required demographic, epidemiologic, and
sexual behavior data for each country from recent household
surveys [30–42] and Spectrum,a modelingsoftware package, which
includes a demographic platform populated with UN population
data [27,43,44]. Country-specific pre-scale-up population charac-
teristics, including size of the adult population, adult population
growthrate,male circumcision and adultHIVprevalence,and HIV
incidence, are shown in Table 1. A complete listing of the data used
for each country is available from the authors upon request.
Cost Data
A breakdown of the VMMC unit cost used in the model is
provided in Table 2. With the exception of the waste management
and supply chain costs, the unit cost components are derived from
a VMMC costing study conducted in Zimbabwe in 2010 as part of
a multi-country study that also included Kenya, Namibia, South
Africa, Uganda, and Zambia [45–50]. Zimbabwe was chosen
because it is one of the first countries to scale up VMMC services
following WHO’s MOVE considerations for more efficient use of
facility space and staff time and for the bundling of the
commodities required to perform VMMC [24]. Information on
required inputs and costs was collected from sites providing
VMMC in Zimbabwe. This includes data on both direct costs
(consumables, staff costs, and training costs) and indirect costs
(capital costs, maintenance and utility costs, support overhead, and
management overhead). Because significant variations in labor
costs were noted across countries, we vary the staff costs by
country, adjusting them by after tax median monthly disposable
salary. We also adjust the costing information collected in the
Zimbabwe study for underreporting on waste management and
other supply chain costs [51]. We base the waste management
costs on a costing analysis conducted in Swaziland, a detailed
description of which is provided elsewhere [52]. The VMMC unit
cost used for each country is shown in Table 3.
For lifetime HIV treatment costs, we use the default discounted
value in the DMPPT model (US$7,400) [25]; we use the same
value for all countries. This value includes costs of AIDS treatment
and care, including ART, treatment of major opportunistic
infections, laboratory tests, and home-based care. The lifetime
HIV treatment cost is based on a unit cost of US$155 for first-line
antiretroviral drugs and US$1,678 for second-line antiretroviral
drugs [53]. We also assume that need for treatment begins after
8 y of infection and that the annual continuation rate on ART is
97.5% [27].
Table 1. Pre-scale-up population characteristics, by country.
Country
Population Aged 15–
49 y (Millions)
Adult Population
Growth Rate
(Percentage)
Male Circumcision
Prevalence
(Percentage)
Adult HIV Prevalence
(Percentage)
Adult HIV Incidence
(Percentage)
Botswana 1.08 2.42 10.2 22.9 2.0
Lesotho 1.06 1.34 0.0 23.6 2.9
Malawi 6.84 3.02 20.7 12.5 1.0
Mozambique 10.32 2.45 59.5 12.9 1.4
Namibia 1.09 2.22 21.0 14.1 0.8
Nyanza Province, Kenya 1.51 2.80 44.8 13.1 1.6
Rwanda 4.49 3.29 10.0 3.1 0.3
South Africa 26.84 0.89 44.7 16.9 2.1
Swaziland 0.59 1.51 8.2 26.4 3.2
Tanzania 19.63 2.89 66.8 6.7 0.8
Uganda 14.16 3.87 24.8 6.5 0.7
Zambia 6.85 2.61 10.8 14.9 1.6
Zimbabwe 6.19 1.50 10.3 17.9 2.2
Table 1 provides the size of the 2008 population aged 15–49 y, adult population growth rate, and adult HIV incidence from Spectrum, which is populated with UN
population data [27,43,44]. The years for the pre-scale-up male circumcision and adult HIV prevalence data are as follows: Botswana (2004) [30], Lesotho (2004) [9,39],
Malawi (2004) [40], Mozambique (2003) [35], Namibia (2007) [38], Nyanza Province, Kenya (2008/2009) [36], Rwanda (2005) [9,34], South Africa (2008), Swaziland (2006/
2007) [32], Tanzania (2007/2008) [42], Uganda (2004) [37], Zambia (2007) [31], and Zimbabwe (2005/2006) [33].
doi:10.1371/journal.pmed.1001132.t001
Table 2. VMMC unit cost components.
Category Cost Component Cost (US$)
Direct costs Consumables 28.67
Waste management 9.39
Other supply chain 10.91
Staff costs Variable
a
Training costs 1.70
Indirect costs Capital costs 0.45
Maintenance and utility costs 3.24
Support overhead 4.42
Management overhead 2.32
Table 2 presents the components of the VMMC unit cost used in this study. The
VMMC unit cost was derived based on a VMMC costing study conducted in
Zimbabwe in 2010 [50] and supplemented with analysis of data from Swaziland.
aWe vary staff costs by country, adjusting them by after tax median monthly
disposable salary.
doi:10.1371/journal.pmed.1001132.t002
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an annual discount rate of 3% on future expenditures and savings
[54] as well as on infections averted [55].
Base Case and Sensitivity Analysis
Our analyses are limited to the scale-up of VMMC services
among males ages 15 to 49 y who are HIV-negative. For all
models, we assume that the scale-up begins in 2011 and that the
pace of scale-up is slower at first, followed by a more rapid scale-
up, and then another slow period of scale-up, to allow for training
and other logistic developments likely to occur in the early stages
of implementation. The model observation period for all models is
2011 to 2025. This allows us to evaluate the 15-y impact of
VMMC more comprehensively.
For the base case, we assume the following:
N VMMC effectiveness—we use 60% for the protective effect of
VMMC and assume that the effect is constant over the model
simulation period [1,56].
N Target VMMC coverage level—male circumcision coverage is
increased from pre-scale-up levels to 80% of HIV-negative
males ages 15 to 49 y.
N Time to 80% scale-up—male circumcision coverage is
increased from pre-scale-up levels to 80% of HIV-negative
males ages 15 to 49 in 5 y, with the coverage target reached by
2015 and maintained at 80% thereafter.
N Post-circumcision behavior change—no post-circumcision
behavior change is associated with VMMC scale-up.
N VMMC unit cost—the VMMC unit cost used for each country
is shown in Table 3.
Given uncertainty in model inputs, we also conduct sensitivity
analyses, exploring various alternative scenarios. We vary VMMC
effectiveness, VMMC coverage level, time to scale-up, level of
post-circumcision behavior change, VMMC unit cost, and lifetime
HIV treatment cost as follows:
N VMMC effectiveness—34% and 77% (versus 60%) [1].
N Target VMMC coverage levels—50% and 100% (versus. 80%).
N Time to 80% scale-up—1, 10, and 15 y (versus 5 y).
N Post-circumcision behavior change—a 30% post-circumcision
behavior change effect is associated with MMC scale-up
(versus no post-circumcision behavior change, or 0%).
N VMMC unit cost—country base case unit cost 620% as
shown in Table 3.
N Lifetime ART cost—ART cost is assumed to decline over
time, leading to a lifetime cost of US$3,400 (versus US$7,400)
[53].
Results
Base Case—80% VMMC Coverage by 2015
The number of additional VMMCs required to achieve 80%
male circumcision coverage by 2015 is presented in Table 4. A
total of 20.34 million VMMCs are required to scale up male
circumcision coverage to 80% by 2015 in Botswana, Lesotho,
Malawi, Mozambique, Namibia, Rwanda, South Africa, Swazi-
land, Tanzania, Uganda, Zambia, Zimbabwe, and Nyanza
Province in Kenya. When taking the longer-term view (to 2025),
an additional 8.42 million VMMCs are required between 2016
and 2025, for a total of almost 29 million VMMCs in the model’s
full study period (2011–2025). The number of VMMCs needed to
achieve 80% male circumcision by 2015 varies by country, with
the largest number of VMMCs required in South Africa (the
country with the largest population and a high adult HIV
prevalence) followed by Uganda (the country with a large and fast-
growing population and low baseline VMMC prevalence),
Malawi, Zambia, and Zimbabwe (also countries low baseline
VMMC prevalence).
We find a strong impact of scaling up VMMC to achieve 80%
coverage by 2015 on the number of adult HIV infections averted.
A total of 430,000 HIV infections are averted in the 13 countries
between 2011 and 2015, while almost 3.36 million HIV infections
are averted by 2025 (Table 4). South Africa is the country with the
largest number of HIV infections averted (with more than 1
million infections averted between 2011 and 2025) followed by
Zimbabwe, Zambia, and Uganda. More than 20% of new HIV
infections are averted between 2011 and 2025 in all countries
except Mozambique, Nyanza Province (Kenya), South Africa, and
Tanzania (the countries with the highest baseline VMMC
Table 3. VMMC unit cost by country.
Country VMMC Unit Cost—Base Case (US$) VMMC Unit Cost Range (US$)
Botswana 78.07 62.45–93.68
Lesotho 83.78 67.03–100.54
Malawi 83.78 67.03–100.54
Mozambique 86.29 69.03–103.55
Namibia 86.60 69.28–103.92
Nyanza Province, Kenya 74.89 59.92–89.87
Rwanda 80.13 64.10–96.16
South Africa 95.15 76.12–114.18
Swaziland 74.83 59.86–89.79
Tanzania 82.56 66.04–99.07
Uganda 65.85 52.68–79.02
Zambia 89.65 71.72–107.58
Zimbabwe 78.23 62.58–93.87
Table 3 shows the country-specific VMMC unit costs used in the study. To obtain the VMMC unit cost for each country, we vary staff costs in each country, adjusting
them by after tax median monthly disposable salary [51]. The range used in the sensitivity analysis is country base case unit cost 620%.
doi:10.1371/journal.pmed.1001132.t003
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of new HIV infections averted, with 42% of new infections averted
between 2011 and 2025. The large benefit of VMMC in
Zimbabwe is largely driven by the currently low prevalence of
VMMC (10.3%) and high HIV prevalence (17.9%) and incidence
(2.2%).
The number of VMMCs required to avert one HIV infection is
calculated by dividing the additional number of VMMCs required
by the number of HIV infections averted over the relevant time
period. For the period 2011–2015, the number of VMMCs per
HIV infection averted ranges from 25 in Swaziland to 239 in
Rwanda, while for the full study period (2011–2025), the number
of VMMCs per HIV infection averted ranges from four in
Zimbabwe to 44 in Rwanda (Table 4). For the period 2011–2025,
the number of VMMCs per HIV infection averted is ten or less in
all countries except Malawi, Namibia, Rwanda, and Uganda, each
of which has a relatively low incidence of HIV.
Although circumcision of HIV-infected men has not been found
to directly reduce HIV transmission to their female partners [57],
and the primary impact of increasing VMMC coverage is to
reduce the number of new HIV infections in men, the number of
new infections in women is also reduced. This occurs by reducing
the exposure of women to HIV-infected men. That is, as HIV
incidence decreases in men following VMMC scale-up, the
probability of women encountering infected male partners
decreases, with a consequent reduction in HIV incidence among
women. The HIV infections averted (presented in Table 4) thus
represent infections averted in both men and women. Figure 2
illustrates the male and female HIV infections averted over time,
by country, for 2011–2025. In all countries, the cumulative
number of male HIV infections averted between 2011 and 2025 is
higher than the cumulative number of female HIV infections
averted. In the early years, the HIV infections averted occur
mostly among men, but over time, the proportion of HIV
infections averted in women steadily increases, with new HIV
infections averted in women representing almost half of the total
HIV infections averted in 2025.
Figure 3 shows the discounted cost of scaling up VMMC to
achieve 80% coverage by 2015 for each of the 13 priority
countries for the period 2011–2015. The cost ranges from
US$12.53 million in Swaziland (the country with the smallest
number of additional VMMCs required) to US$376.55 million in
Table 4. Impact of VMMC on HIV infections averted in base case, by country, 2011–2015 and 2011–2025.
Country Time Period
Additional VMMCs
(Millions)
HIV Infections
Averted (Millions)
HIV Infections
Averted (Percentage)
VMMC per HIV
Infection Averted
Botswana 2011–2015 0.35 0.01 12 36
2011–2025 0.49 0.06 28 8
Lesotho 2011–2015 0.38 0.01 12 28
2011–2025 0.54 0.11 37 5
Malawi 2011–2015 2.10 0.03 11 66
2011–2025 3.04 0.24 28 13
Mozambique 2011–2015 1.06 0.03 5 38
2011–2025 1.53 0.22 13 7
Namibia 2011–2015 0.33 0.00 9 109
2011–2025 0.48 0.02 25 26
Nyanza Province, Kenya 2011–2015 0.38 0.01 6 36
2011–2025 0.57 0.07 16 8
Rwanda 2011–2015 1.75 0.01 10 239
2011–2025 2.53 0.06 29 44
South Africa 2011–2015 4.33 0.14 7 30
2011–2025 5.94 1.08 20 5
Swaziland 2011–2015 0.18 0.01 12 25
2011–2025 0.27 0.06 34 5
Tanzania 2011–2015 1.38 0.02 3 56
2011–2025 1.98 0.20 9 10
Uganda 2011–2015 4.25 0.05 10 91
2011–2025 6.35 0.34 25 19
Zambia 2011–2015 1.95 0.04 12 43
2011–2025 2.87 0.34 30 8
Zimbabwe 2011–2015 1.91 0.06 13 31
2011–2025 2.17 0.57 42 4
Total 2011–2015 20.34 0.43 8 47
2011–2025 28.76 3.36 22 9
Table 4 presents the additional VMMCs and the impact of VMMC on HIV infections averted for 2011–2015 and 2011–2025 for the base case scenario. HIV infections
averted are not discounted.
doi:10.1371/journal.pmed.1001132.t004
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VMMCs required), with a total of US$1,520,000,000 needed to
scale up VMMC coverage to 80% in the 13 countries by 2015.
The cost for the period 2011–2025 is shown in the first column of
Table 5. A total of over US$2,000,000,000 is needed to scale up
VMMC coverage to 80% by 2015 and maintain this level of
coverage in the 13 countries until 2025.
Combining the cost data with the number of HIV infections
averted, we obtain the discounted cost per HIV infection averted.
The cost per HIV infection averted for the period 2011–2025
ranges from US$369 in Zimbabwe, where adult HIV prevalence is
17.9%, to US$4,096 in Rwanda, where adult HIV prevalence is
lower than in any of the other 13 countries studied (3.1%). The
overall cost per HIV infection averted for 2011–2025 for all 13
countries is US$809.
Finally, we calculate the net savings associated with VMMC
scale-up. The savings due to future ART costs avoided (with the
discounted value of lifetime HIV treatment costs estimated at
US$7,400 per infection) minus the discounted VMMC costs
amount to US$16,510,000,000 for the 13 countries from 2011 to
2025 (Table 5). The net savings can also be combined with the
number of HIV infections averted to obtain the net savings per
HIV infection averted. For 2011–2025, this value ranges from
US$3,304 in Rwanda to US$7,031 in Zimbabwe. The overall net
savings per HIV infection averted for 2011–2025 for all 13
countries is US$6,608.
Sensitivity Analysis
Table 6 presents the results of the sensitivity analysis. The table
provides the values for the HIV infections averted, the number of
VMMCs per HIV infection averted, the cost per HIV infection
averted, and the net savings per HIV infection averted for 2011–
2025 for each parameter examined. The values for the base
scenario (80% male circumcision coverage within 5 y) are shown
in the third column of Table 6.
The results help to confirm the internal consistency of the
DMPPT model and show that, in large measure, the VMMC
impact, cost, and savings results that we observe in the base case
are robust to changes in VMMC effectiveness, VMMC coverage,
time to scale-up, level of post-circumcision behavior change,
VMMC unit cost, and lifetime HIV treatment cost.
Our analysis varying VMMC effectiveness shows that even if we
assume much reduced effectiveness (34% instead of 60%), high
numbers of infections are averted and net savings per infection
Figure 2. HIV infections averted in base case, by male and female, by country, 2011–2025. Figure 2 provides data for males and females
for 2011–2025 for the base case scenario in which 80% coverage of VMMC is reached in 2015 and maintained thereafter, and there is no post-
circumcision risk behavior change.
doi:10.1371/journal.pmed.1001132.g002
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target is reduced from 80% to 50% or if the time to achieve 80%
VMMC coverage is increased to 10 or 15 y.
To assess the potential impact of post-circumcision risk behavior
change, the model calculates the impact of risky sexual behaviors
reverting to patterns that existed earlier in the epidemic, prior to the
scale-up of VMMC services. It should be noted that this impact is
different from the early resumption of sexual activity before complete
wound healing that can also be an issue of concern in the context of
expanding VMMC services. The impact is the result of behavior
change due to a false perception that VMMC has eliminated the risk
of HIV transmission. As compared to no post-circumcision risk
behavior change, assuming 30% post-circumcision risk behavior
changeresultsinadecreaseintheHIVinfectionsaverted,anincrease
in the numbers of VMMCs per HIV infection averted, an increase in
the cost per HIV infection averted, and a decrease in net savings. In
all of the countries studied except Rwanda, VMMC scale-up remains
cost saving, even with 30% post-circumcision risk behavior change.
In Rwanda, the country with the lowest HIV prevalence, scaling up
VMMC in the presence of this level of post-circumcision risk
behavior leads to an increase in the number of new HIV infections.
Predictably, decreasing (increasing) the base case VMMC unit
cost by 20% results in a decrease (increase) in the cost per HIV
infection averted and an increase (decrease) in the net savings per
HIV infection averted in countries. Assuming the lower VMMC
unit cost for each country, the cost and net savings associated
with scaling up VMMC coverage to 80% by 2015 and
maintaining this level of coverage in the 13 countries until 2025
are US$1,620,000,000 and US$16,900,000,000 instead of
US$2,020,000,000 and US$16,510,000,000 in the base case.
Assuming the higher VMMC unit cost, the cost of scaling up
VMMC services in the 13 countries is US$2,430,000,000,
resulting in net savings of US$16,090,000,000.
Reducing lifetime ART cost from US$7,400 to US$3,400 does
significantly reduce the net savings per infection averted in all
countries, although it remains well above US$2,000 in almost all
countries. Rwanda is the only country where such a reduction in
lifetime ART cost would lead to net losses per infection averted.
Net savings associated with scaling up VMMC coverage is reduced
to US$6,480,000,000 in the 13 countries if lifetime ART cost is
US$3,400.
Discussion
To support decision making and planning for VMMC scale-up
in Botswana, Lesotho, Malawi, Mozambique, Namibia, Rwanda,
Figure 3. Cost for scaling up VMMC coverage in base case, by country, 2011–2015. Figure 3 provides the discounted cost of scaling up
VMMC coverage for 2011–2015 for the base case scenario in which 80% coverage of VMMC is reached in 2015 and maintained thereafter, and there is
no post-circumcision risk behavior change.
doi:10.1371/journal.pmed.1001132.g003
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and Nyanza Province in Kenya, we estimate the country-specific
impact and cost of scaling up VMMC services using the DMPPT
model developed by the USAID and UNAIDS. Our study suggests
that rapid scale-up of VMMC in eastern and southern Africa is
warranted based on the likely impact on the region’s HIV
epidemics and the resultant cost savings.
Model results also show that, although the primary impact of
scaling up VMMC coverage is to reduce the number of new HIV
infections in men, the intervention also prevents HIV infections in
women. While the cumulative number of male HIV infections
averted between 2011 and 2025 is higher than the cumulative
number of female HIV infections averted, the proportion of HIV
infections averted in women steadily increases until HIV infections
averted in women represent almost half of the new HIV infections
averted in 2025.
Our results show that the costs per infection averted are
comparable to the estimated cost per infection averted of a
number of key HIV prevention interventions implemented in the
region. The cost per HIV infection averted, which ranges from
US$369 in Zimbabwe to US$4,096 in Rwanda, is below US$1,000
in all countries except Malawi, Namibia, Rwanda, and Uganda.
These costs per infection averted are comparable to those of
prevention of vertical transmission (US$663 per HIV-positive
birth averted), voluntary counseling and testing (US$1,315 per
HIV infection averted), and prevention of STIs (US$321–
US$1,665) [58].
Our results are somewhat sensitive to changes in VMMC
effectiveness, VMMC coverage targets, time to scale-up, and
VMMC cost. Nonetheless, all of the values tested for these
parameters resulted in lives saved and cost savings for all countries.
It is especially important to note that even if VMMC coverage is
scaled up to 50% in 5 y instead of to 80%, high numbers of
infections will be averted and net savings per infection averted will
be obtained in all countries except Mozambique and Tanzania—
the two countries where pre-scale-up coverage is higher than 50%.
This is critical because even though there is no evidence available
yet on the feasibility of scaling up VMMC coverage to 80%, there
is evidence that VMMC coverage rates of above 50% can be
reached through VMMC scale-up efforts [56].
Similar to the results reported by other authors, our results
suggest that post-circumcision risk behavior change is unlikely to
completely reverse the benefits of male circumcision, with the
possible exception of Rwanda. In the case of Rwanda, the low
incidence of HIV (0.3%) means that risk compensation associated
with male circumcision could actually make the epidemic worse.
In the remaining countries, the negative consequences from a 30%
risk compensation would be insufficient to fully reverse the benefits
of VMMC. In all countries, it is critical that VMMC programs
emphasize that male circumcision is not 100% protective and that
condom use and other behavioral risk reductions remain essential
[8,59]. Effective messaging in this regard is critical to ensure that
men and their sexual partners do not increase their sexual risk
behaviors following VMMC scale-up.
This study has a number of limitations. Because this model was
designed primarily for advocacy purposes, certain elements are not
modeled, including treatment, a more fully articulated age
structure, and force of infection, which probably leads to an
overestimate of the impact of male circumcision.
Another limitation is that we use pre-scale-up male circumcision
coverage estimates based on men’s self-reported circumcision
status in household surveys. There is some evidence that
uncircumcised and partially circumcised men may report being
circumcised in some populations [60]. Unfortunately, there is no
information available on the prevalence of this phenomenon in the
countries studied. In the one country where partial circumcision is
known to be widely practiced (Lesotho), we assume baseline
VMMC prevalence to be at 0% rather than using the self-reported
data.
Additional limitations relate to our cost assumptions. Ideally, we
would have obtained country-specific VMMC unit cost estimates
based on the MOVE model instead of only adjusting the staff costs
by country based on after-tax median monthly disposable salary.
However, this model for delivering VMMC was available in only a
Table 5. Total cost and net savings per HIV infection averted for base case scenario, by country, 2011–2025.
Country
Cost of VMMC Scale-Up,
2011–2025 (US$ Millions)
Cost per HIV Infection
Averted, 2011–2025 (US$)
Net Savings, 2011–2025
(US$ Millions)
Net Savings per HIV
Infection Averted, 2011–
2025 (US$)
Botswana 32.79 693 317.14 6,707
Lesotho 34.97 442 550.57 6,958
Malawi 218.46 1,216 1,110.98 6,184
Mozambique 113.32 704 1,077.25 6,696
Namibia 35.52 2,558 67.21 4,842
Nyanza Province, Kenya 36.38 660 371.23 6,740
Rwanda 173.78 4,096 140.21 3,304
South Africa 489.47 605 5,498.55 6,795
Swaziland 17.18 406 295.88 6,994
Tanzania 140.40 950 953.74 6,450
Uganda 357.29 1,408 1,520.36 5,992
Zambia 220.42 869 1,679.41 6,623
Zimbabwe 153.84 369 2,930.64 7,031
Total 2,023.80 809 16,513.15 6,608
Table 5 provides the discounted cost of scaling up VMMC coverage, cost per HIV infection averted, and net savings per HIV infection averted for 2011–2025 for the base
case scenario. HIV infections averted are discounted.
doi:10.1371/journal.pmed.1001132.t005
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than that used in previous studies [8,11,59,61,62], reflects a better
understanding of the service delivery components required for
such a program, including waste management and logistics
associated with the scaling up of VMMC services [52]. It should
also be noted that countries are procuring the same circumcision
kits and are adopting the same service delivery model that was
costed in this study. If possible, we would also have adjusted
VMMC unit cost over time and scale [63,64]. However, no
information is currently available on how VMMC unit cost might
vary over time and with scale. Another limitation is that we do not
include costs associated with demand creation in our study [65].
Finally, it would have been preferable for us to obtain country-
specific ART costs; however, country-specific data for the 13
countries studied were not available.
HIV prevalence and incidence estimates used in the model and
how they compare to the actual present and projected prevalence
and incidence in each of the selected countries is another factor
that affects the accuracy of our findings. A steeper decline in
baseline incidence, for example, will result in fewer infections
averted as a result of VMMC. Conversely, if these incidence trends
are overly optimistic, then the number of infections available to be
averted by VMMC may in turn be larger than estimated here.
We also recognize that our modeling assumes that males seeking
out VMMC services are typical of the general male population in
the selected age range. If, for example, those seeking out VMMC
services are in fact those who are at least risk of becoming infected
(perhaps VMMC clients already disproportionately use condoms),
then the benefits of VMMC are likely to be overestimated.
Conversely, if those who are at most risk of infection (those with a
large number of partners and/or low condom use) are dispropor-
tionately attracted to VMMC services, then the modeling
presented in this paper may underestimate the value of VMMC
scale-up. Given that VMMC client sexual behavior, relative to the
behavior of the general male population, remains unknown, it is
not possible to determine whether our projections are underesti-
mated or overestimated.
There are also a number of prevention benefits that are
indirectly associated with seeking out VMMC services. These
include the benefits of counseling and testing, STI treatment, and
early antiretroviral treatment. For example, for those males who
seek out VMMC services but find that they are already HIV-
infected, there could be societal prevention benefits if these men
subsequently are able to access early treatment and reduce their
infectivity. Since we focus only on the direct benefits received by
those receiving VMMC and do not quantify any additional
benefits of counseling and testing, STI treatment, and early
antiretroviral treatment as a result of seeking VMMC services, it is
possible that the prevention benefits of VMMC could be
underestimated.
The past year has been marked by important advances in HIV
prevention, including the finding that early treatment initiation
reduces sexual transmission by as much as 96% in stable
serodiscordant couples [66]. However, the population-level impact
of treatment is not currently well known. And coverage of those
eligible for antiretroviral treatment under WHO guidelines
remains low, with less than half of people needing treatment
having access to it in eastern and southern Africa in 2010 [67].
VMMC is a one-time surgical procedure with the promise of
substantial impact on population-level HIV incidence. Its effects
accrue to both men and women, and it compares favorably with
other HIV prevention programs in terms of cost-effectiveness.
Countries are adopting WHO/UNAIDS recommendations to
incorporate VMMC within their HIV prevention portfolios. Best
practices from Kenya [68], Tanzania [69], and South Africa [56]
show that with government leadership, community involvement,
and collaboration among partners, it is possible to scale up rapidly
by implementing service delivery models that take into consider-
ation available resources, efficiency, and quality to achieve the
maximum public health impact. To ensure that high coverage
rates are achievable, countries and their international partners
should allocate enough resources to take advantage of the returns
on investment predicted for this biomedical HIV prevention
modality.
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Background. Every year, about 2.5 million people (mainly
in sub-Saharan Africa) become infected with HIV, the virus
that causes AIDS. There is no cure for HIV/AIDS.
Consequently, prevention of HIV transmission is very
important. Because the most common HIV transmission
route is through unprotected sex with an infected partner,
individuals can reduce their risk of HIV infection by
abstaining from sex, by having only one or a few partners,
and by using male or female condoms. There is also strong
evidence that voluntary medical male circumcision
(VMMC)—the removal of the foreskin, the loose fold of
skin that covers the head of the penis—reduces the
heterosexual acquisition of HIV in men by about 60%. In
2007, the World Health Organization (WHO) and the Joint
United Nations Programme on HIV/AIDS (UNAIDS)
recommended that VMMC should be offered to men as
part of comprehensive HIV risk reduction programs in
settings with generalized HIV epidemics and low levels of
male circumcision. They also prioritized 13 countries in
eastern and southern Africa for VMMC program scale-up.
Why Was This Study Done? The impact of VMMC scale-
up in terms of HIV infections and AIDS deaths averted
(epidemiologic impact) is expected to be large, and the
intervention should also reduce the costs associated with the
treatment, care, and support of infected individuals.
However, VMMC scale-up will require substantial funding
and considerable effort by countries—many of which have
weak health systems and limited resources—to train
personnel, equip facilities, and provide the necessary
commodities. To support planning for VMMC scale-up, the
United States Agency for International Development Health
Policy Initiative has collaborated with UNAIDS to develop the
Decision Makers’ Program Planning Tool (DMPPT), a
mathematical model that allows analysts and decision
makers to estimate the epidemiologic impact and cost of
alternative VMMC scale-up programs. In this study, the
researchers use DMPPT to estimate the impact and cost of
scaling up adult VMMC in the 13 priority countries in eastern
and southern Africa.
What Did the Researchers Do and Find? The researchers
derived VMMC unit costs for each priority country based on a
cost assessment undertaken in Zimbabwe, one of the first
countries to scale up VMMC services using WHO’s ‘‘Models
for Optimizing Volume and Efficiencies’’ (MOVE) guidelines.
They fed these costs and recent epidemiologic data
(including HIV infection rates and the effectiveness of
VMMC in preventing HIV transmission) and demographic
data (including the adult population size and pre-scale-up
male circumcision prevalence) collected in each country into
the DMPPT, together with information on the lifetime costs
of HIV treatment. Results from running the DMPPT model
suggest that scaling up adult VMMC to reach 80% coverage
in the 13 priority countries by 2015 would require 20.33
million circumcisions to be completed between 2011 and
2015. To maintain this coverage, a further 8.42 million
circumcisions would be required between 2016 and 2025.
Such a scale-up would avert 3.36 million new HIV infections
through 2025 and would cost US$2,000,000,000 between
2011 and 2025. However, it would result in net savings
(because of averted treatment and care costs) of
US$16,510,000,000.
What Do These Findings Mean? These findings suggest
that rapid VMMC scale-up in eastern and southern Africa is
warranted, given its likely impact on the region’s HIV
epidemics and the resultant cost savings. However, the
accuracy of these findings depends on the assumptions built
into the DMPPT and on the data fed into it. For example,
there could be risk behavior changes after circumcision. That
is, risky sexual behaviors may increase in men who have
been circumcised. However, the researchers show that,
except in Rwanda, post-circumcision risk behavior change
is unlikely to completely reverse the benefits of VMMC. These
modeling results also assume that men seeking out VMMC
services are typical of the general male population, but if
they are actually at unusually low risk of HIV infection, then
the benefits of VMMC reported here are likely to be
overestimated. Finally, these findings assume 80% VMMC
coverage. This may be optimistic, although results from
Kenya indicate that this target is achievable. Thus, countries
and their international partners must allocate sufficient
resources to VMMC scale-up to achieve high coverage
rates if they are to take full advantage of the benefits
predicted here for VMMC scale-up.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001132.
N This study is part of a PLoS Collection of articles on VMMC
(http://www.ploscollections.org/VMMC2011) and is further
discussed in a PLoS Medicine Review Article by Hankins
et al. (http://dx.doi.org/10.1371/journal.pmed.1001127)
N Information is available from WHO, UNAIDS, and PEPFAR
on all aspects of HIV/AIDS; the 2011WHO/UNAIDS progress
report on VMMC scale-up in the 13 priority countries is
available
N NAM/aidsmap provides basic information about HIV/AIDS,
summaries of recent research findings on HIV care and
treatment, and information on male circumcision for the
prevention of HIV transmission
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on all aspects of HIV prevention, and on HIV/AIDS in
Africa (in English and Spanish)
N The Clearinghouse on Male Circumcision, a resource
provided by WHO, UNAIDS, and other international bodies,
provides information and tools for VMMC policy develop-
ment and program implementation, including information
on the DMPPT and the MOVE guidance
N Personal stories about living with HIV/AIDS are available
through Avert, through NAM/aidsmap, and through the
charity website Healthtalkonline
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